New inflammatory disease drug passes first safety tests in humans
NCT ID NCT05662033
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 27 times
Summary
This early-stage study tested a new drug called AZD6793 in 93 people, mostly healthy volunteers and a few with COPD. The main goal was to check if the drug is safe and how the body processes it. Researchers gave different doses as a liquid or tablet, with and without food. This is a first step to see if the drug is promising enough for larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Harrow, HA1 3UJ, United Kingdom
-
Research Site
Wythenshawe, M23 9QZ, United Kingdom
Conditions
Explore the condition pages connected to this study.